Cytosolic β-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease

[1]  H. Morita,et al.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. , 2003, Lancet.

[2]  P. Pini.  Introducing the most wanted Lancet articles , 2003, The Lancet.

[3]  H. Morita,et al.  RETRACTED: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial , 2003, The Lancet.

[4]  A. Woolf,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[5]  Hung-Fat Tse,et al.  Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation , 2003, The Lancet.

[6]  T. Heikkinen,et al.  The common cold , 2003, The Lancet.

[7]  Bernd Westphal,et al.  Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.

[8]  J. Boura,et al.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction : a quantitative review of 23 randomised trials , 2022 .

[9]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[10]  C. Link,et al.  Interaction of intracellular β amyloid peptide with chaperone proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Butterfield,et al.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: Potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress , 2002 .

[12]  G. Plant,et al.  Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid‐Dan and Amyloid‐Beta , 2002, Journal of neuropathology and experimental neurology.

[13]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[14]  C. Link,et al.  Interaction of intracellular beta amyloid peptide with chaperone proteins. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[16]  A. Bush,et al.  Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts. , 2001, Novartis Foundation symposium.

[17]  Jack Liang.  Interaction between β‐amyloid and lens αB‐crystallin , 2000 .

[18]  D. Smith,et al.  The major in vivo modifications of the human water-insoluble lens crystallins are disulfide bonds, deamidation, methionine oxidation and backbone cleavage. , 2000, Experimental eye research.

[19]  J. Horwitz.  The function of alpha-crystallin in vision. , 2000, Seminars in cell & developmental biology.

[20]  P. Greengard,et al.  Intraneuronal Aβ42 Accumulation in Human Brain , 2000 .

[21]  J. Liang.  Interaction between beta-amyloid and lens alphaB-crystallin. , 2000, FEBS letters.

[22]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[23]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[24]  W. W. Jong,et al.  The Molecular Chaperone aB-crystallin Enhances Amyloid Neurotoxicity , 1999 .

[25]  C. Masters,et al.  Aqueous Dissolution of Alzheimer’s Disease Aβ Amyloid Deposits by Biometal Depletion* , 1999, The Journal of Biological Chemistry.

[26]  R. Tanzi,et al.  Differential effects of apolipoprotein E isoforms on metal-induced aggregation of A beta using physiological concentrations. , 1999, Biochemistry.

[27]  W. D. de Jong,et al.  The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. , 1999, Biochemical and biophysical research communications.

[28]  R. Doms,et al.  Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture , 1998, The Journal of cell biology.

[29]  C. Masters,et al.  Relative Increase in Alzheimer’s Disease of Soluble Forms of Cerebral Aβ Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain* , 1998, The Journal of Biological Chemistry.

[30]  J. Harding.  Alzheimer disease and cataract: common threads. , 1997, Alzheimer disease and associated disorders.

[31]  J. Piatigorsky,et al.  Oxidative Stress Increases Production of -Amyloid Precursor Protein and -Amyloid (A) in Mammalian Lenses, and A Has Toxic Effects on Lens Epithelial Cells (*) , 1996, The Journal of Biological Chemistry.

[32]  J. Piatigorsky,et al.  Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid (Abeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. , 1996, The Journal of biological chemistry.

[33]  Dr. Gareth Griffiths.  Fine Structure Immunocytochemistry , 1993, Springer Berlin Heidelberg.

[34]  R. Mayer,et al.  Ballooned neurons in several neurodegenerative diseases and stroke contain αB crystallin , 1992 .

[35]  S. Vaezy,et al.  A quantitative analysis of transparency in the human sclera and cornea using Fourier methods , 1991, Journal of microscopy.

[36]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[37]  D. Selkoe,et al.  Amyloid β-protein deposition in tissues other than brain in Alzheimer's disease , 1989, Nature.

[38]  D. Selkoe,et al.  Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. , 1989, Nature.

[39]  K. Grzeschik,et al.  The precursor of Alzheimer??s disease amyloid A4 protein resembles a cell-surface receptor , 1987 .

[40]  L. Chylack,et al.  Classification of human senile cataractous change by the American Cooperative Cataract Research Group (CCRG) method: II. Staged simplification of cataract classification. , 1984, Investigative ophthalmology & visual science.

[41]  L. Chylack.  Classification of human cataractous change by the American Cooperative Cataract Research Group method. , 1984, Ciba Foundation symposium.

[42]  A. Spector.  Oxidation and cataract. , 1984, Ciba Foundation symposium.

[43]  G. Benedek,et al.  Theory of transparency of the eye. , 1971, Applied optics.

[44]  R. Lowe.  THE EYES IN MONGOLISM , 1949, The British journal of ophthalmology.